SPORE in Endometrial Cancer

子宫内膜癌中的孢子

• 批准号: 7934596
• 负责人: Paul Joseph Goodfellow
• 金额: $ 50万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-18 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7934596
• 关键词: Adjuvant; Biological Response Modifier Therapy; Biometry; Cancer Biology; Cancer Center; Commit; Detection; Development; Diagnosis; Endometrial Carcinoma; FGFR2 gene; Family member; Genetic; Hospitals; Inherited; Investigation; Lead; Malignant Neoplasms; Marriage; Methylation; Mismatch Repair; Morbidity - disease rate; Outcome; Pathology; Pathway interactions; Patients; Play; Population; Prevention; Prognostic Marker; Recruitment Activity; Recurrence; Research; Research Personnel; Research Priority; Research Project Grants; Risk; Role; Signal Transduction; Specialized Program of Research Excellence; Tissues; Training; Translational Research; Universities; Uterine Cancer; Uterine Neoplasms; Washington; Woman; Work; anticancer research; career development; clinical practice; design; follower of religion Jewish; improved; innovation; medical schools; mortality; novel; novel strategies; prevent; programs; therapeutic target

This Specialized Program of Research Excellence (SPORE) in Endometrial Cancer is submitted by Washington University in St. Louis, the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. It includes four research projects, three supportive cores, and research and career development programs. This proposal brings together basic and applied investigators to conduct innovative and diverse translational investigations aimed at preventing, diagnosing and treating endometrial cancer. The four projects in our application have been carefully designed to have significant potential to change clinical practice within five years. Project 1: FGFR2 as therapeutic target in endometrial cancer Project 2: Methylation markers for prognosis in endometrioid endometrial cancers Project 3: Identifying inherited endometrial cancer & the environmental and genetic factors contributing to somatic loss of mismatch repair Project 4: Novel effectors of ERK signaling and their potential roles in the treatment of endometrial cancer The four projects represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University and our collaborators. The critical objectives that we have chosen to focus on are to: 1) improve the treatment of patients with persistent or recurrent endometrial cancer using a molecularly targeted therapy and determine if upfront adjuvant biologic therapies hold promise for improving outcomes in the general endometrial cancer population; 2) develop prognostic markers to help guide the treatment of women with the most common form of uterine tumors, endometrioid endometrial cancer; 3) optimize detection of those women with inherited forms of endometrial cancer so they and their at-risk family members can receive risk-appropriate (intensified) cancer surveillance; and 4) elucidate the role novel effectors of ERK signaling play in uterine cancer and assess opportunities for targeting these in the treatment of endometrial cancers. Three Cores will support these projects: Administration, Tissue & Pathology, and Biostatistics. The Developmental Research Program will support a pathway for continued identification and support of diverse research that could replace or improve current projects, and a Career Development Program will recruit and support candidates committed to training in translational research in endometrial cancer.

这个子宫内膜癌卓越研究（SPORE）的专业计划由圣路易斯的华盛顿大学、巴恩斯犹太医院的Siteman癌症中心和华盛顿大学医学院提交。它包括四个研究项目，三个支持核心，以及研究和职业发展计划。该提案汇集了基础和应用研究人员，以进行旨在预防，诊断和治疗子宫内膜癌的创新和多样化的转化研究。我们申请的四个项目经过精心设计，具有在五年内改变临床实践的巨大潜力。 项目一： FGFR 2作为子宫内膜癌治疗靶点 项目二： 子宫内膜样癌的甲基化标志物与预后 项目三： 识别遗传性子宫内膜癌&导致体细胞错配修复缺失的环境和遗传因素 项目4： ERK信号通路的新效应物及其在子宫内膜癌治疗中的作用 这四个项目代表了子宫内膜癌研究重点与华盛顿大学和我们合作者的优势之间精心选择的婚姻。我们选择关注的关键目标是：1）使用分子靶向治疗改善持续性或复发性子宫内膜癌患者的治疗，并确定前期辅助生物治疗是否有望改善一般子宫内膜癌人群的结局; 2）开发预后标志物，以帮助指导最常见的子宫肿瘤形式，子宫内膜样癌的妇女的治疗; 3）优化对遗传性子宫内膜癌妇女的检测，使她们及其高危家庭成员能够接受风险适当的（强化的）癌症监测; 4）阐明ERK信号传导的新型效应物在子宫癌中的作用，并评估在子宫内膜癌治疗中靶向这些效应物的机会。 三个核心将支持这些项目：管理，组织和病理学，生物统计学。发展研究计划将支持一条途径，继续识别和支持可以取代或改进当前项目的各种研究，职业发展计划将招募和支持致力于子宫内膜癌转化研究培训的候选人。